Retrospective Evidence and Prospective Trials in Dogs

Aging is more than disease—it’s the steady decline of function. In this episode of Longevity by Design, Dr. Gil Blander speaks with physicist-turned-biotech innovator Dr. Peter Fedichev about why resilience, not diseases, holds the key to longer lives.

Peter explains how his background in theoretical physics shaped his approach to biology and aging. He outlines why startups, not large institutions, are now leading innovation in longevity science. Drawing from physics, he describes aging as a series of “jumps” between states, each leaving the body more fragile.

The discussion moves from the limits of current drugs to the promise of new approaches. Peter argues that reducing fluctuations and increasing molecular fidelity could unlock far greater gains in healthspan and lifespan. Listeners gain a fresh lens on what drives aging, where the real breakthroughs may come from, and why the next frontier in longevity will require rethinking the problem altogether.

Guest-at-a-Glance

💡 Name: Peter Fedichev

💡 What they do: Founder & CEO

💡 Company: Gero (biotech company using AI to study aging)

💡 Noteworthy: Physicist turned biotech leader applying statistical physics to model biological age and resilience

💡 Where to find them: LinkedIn

Episode highlights:

[00:00:00] Opening Thoughts on Venture Capital
[00:00:58] Host Introduction and Show Welcome
[00:01:25] Guest Background: From Physics to Biotech
[00:02:42] Physics as a Tool for Biology
[00:05:19] Why Switch From Physics to Biology
[00:06:20] Discovering Aging Through Naked Mole Rats
[00:09:27] Defining Professional Goal in Aging
[00:10:15] Challenges in Crossing Disciplines
[00:11:58] Startups Driving Scientific Innovation
[00:14:09] Pharma, Biotech, and Market Dynamics
[00:16:23] Aging as a System-Level Problem
[00:18:56] Drugs With Modest Longevity Effects
[00:20:14] Aging vs. Disease: Functional Decline
[00:23:48] Squaring the Curve vs. True Aging
[00:26:02] Sponsor Message: InsideTracker
[00:26:56] Resilience in 90-Year-Olds
[00:27:55] Measuring Health With Longitudinal Data
[00:30:07] Aging as Jumps Between States
[00:31:49] Declining Recovery Times With Age
[00:33:33] Cancer Risk and Immune Decline
[00:34:30] Rare Events Driving Aging Jumps
[00:36:15] Mutations, Epimutations, and Reliability Theory
[00:38:31] Perfect Storm Failures in Aging
[00:40:26] Cancer, Diabetes, and System Crashes
[00:42:09] Searching for a Master Switch
[00:43:41] Reducing Physiological Noise to Slow Aging
[00:45:54] Targeting Fluctuations as Drug Strategy
[00:47:13] Stress, Hormesis, and Adaptation
[00:49:27] Evolutionary Role of Stress Responses
[00:50:58] Model Organisms: Mice vs. Dogs
[00:53:41] Why Dogs Mirror Human Aging
[00:55:42] Regulatory Edge: Aging Trials in Dogs
[00:56:42] Next-Gen Drugs Beyond GLP-1
[00:58:22] Epigenetic Rejuvenation vs. Noise Control
[01:00:11] Key Targets: Chromatin Modifiers
[01:01:10] Measuring Fluctuations With Biomarkers
[01:02:58] Dogs as Proof-of-Concept Model
[01:03:23] Defining Jumps Through Omics Data

We Appreciate You!
As a token of our gratitude, we’re excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcast


For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast